Essen BioScience, Inc. and Nycomed Announce Ion Channel Drug Discovery Collaboration

Published: Jun 21, 2010

ANN ARBOR, Mich. & ZURICH--(BUSINESS WIRE)--Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services – and Nycomed – a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

Back to news